Media stories about Apollo Endosurgery (NASDAQ:APEN) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Apollo Endosurgery earned a news impact score of 0.05 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.9645643495478 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several brokerages have issued reports on APEN. ValuEngine raised Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Roth Capital set a $10.00 price target on Apollo Endosurgery and gave the stock a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research lowered Apollo Endosurgery from a “buy” rating to a “hold” rating in a research note on Wednesday, December 27th. Finally, Northland Securities reaffirmed a “buy” rating and set a $12.00 price target on shares of Apollo Endosurgery in a research note on Tuesday, November 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $9.44.
Shares of Apollo Endosurgery (NASDAQ APEN) opened at $6.31 on Friday. Apollo Endosurgery has a 52 week low of $3.55 and a 52 week high of $17.48. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.00 and a current ratio of 2.54. The stock has a market capitalization of $109.10, a PE ratio of -0.17 and a beta of 0.44.
In related news, VP Bret Schwartzhoff bought 9,500 shares of the stock in a transaction dated Tuesday, November 7th. The stock was bought at an average price of $4.24 per share, with a total value of $40,280.00. Following the purchase, the vice president now owns 15,631 shares in the company, valued at approximately $66,275.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Stonepine Capital, L.P. bought 5,163 shares of the stock in a transaction dated Saturday, December 29th. The stock was bought at an average cost of $5.56 per share, with a total value of $28,706.28. Following the purchase, the insider now owns 2,560,314 shares in the company, valued at approximately $14,235,345.84. The disclosure for this purchase can be found here. In the last three months, insiders bought 273,386 shares of company stock valued at $1,328,331. 74.20% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Apollo Endosurgery (APEN) Stock Price” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-apollo-endosurgery-apen-stock-price.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.